Published in J Clin Sleep Med on February 15, 2014
Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases. Innov Clin Neurosci (2016) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep (1991) 44.17
Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage (1999) 40.38
Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron (2002) 33.99
Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage (1999) 29.82
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
Automatically parcellating the human cerebral cortex. Cereb Cortex (2004) 18.32
Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage (2001) 12.61
Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep (2005) 6.64
Obstructive sleep apnoea. Lancet (2002) 6.37
Accurate and robust brain image alignment using boundary-based registration. Neuroimage (2009) 6.27
Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep (1986) 6.04
How many subjects constitute a study? Neuroimage (1999) 5.21
Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature. Neuroimage (2010) 4.55
Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A (2003) 4.21
Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia (1994) 3.46
Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. Neuroimage (2006) 3.28
Brain morphology associated with obstructive sleep apnea. Am J Respir Crit Care Med (2002) 3.18
Reducing interscanner variability of activation in a multicenter fMRI study: controlling for signal-to-fluctuation-noise-ratio (SFNR) differences. Neuroimage (2006) 3.11
Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA (2009) 3.04
Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J (2007) 2.98
Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep (2004) 2.88
Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am J Respir Crit Care Med (2010) 2.78
The neuropsychological effects of obstructive sleep apnea: a meta-analysis of norm-referenced and case-controlled data. Sleep (2003) 2.53
Behavioral and anatomical correlates of chronic episodic hypoxia during sleep in the rat. J Neurosci (2001) 2.47
Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res (2002) 2.33
Individual differences in adult human sleep and wakefulness: Leitmotif for a research agenda. Sleep (2005) 2.20
Variability in fMRI: an examination of intersession differences. Neuroimage (2000) 2.01
Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther (2009) 1.88
Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging (2012) 1.86
Long-term intermittent hypoxia: reduced excitatory hypoglossal nerve output. Am J Respir Crit Care Med (2004) 1.76
Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci (2008) 1.72
Stability, repeatability, and the expression of signal magnitude in functional magnetic resonance imaging. J Magn Reson Imaging (1999) 1.67
Functional imaging of working memory in obstructive sleep-disordered breathing. J Appl Physiol (1985) (2005) 1.64
Cognitive dysfunction in patients with obstructive sleep apnea (OSA): partial reversibility after continuous positive airway pressure (CPAP). Brain Res Bull (2003) 1.62
Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J (2009) 1.62
Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science (2008) 1.61
Variability in fMRI: a re-examination of inter-session differences. Hum Brain Mapp (2005) 1.59
The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep (1992) 1.54
Impaired spatial learning and hyperactivity in developing rats exposed to intermittent hypoxia. Pediatr Res (2002) 1.39
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc (2009) 1.38
Reduced brain gray matter concentration in patients with obstructive sleep apnea syndrome. Sleep (2010) 1.33
Intermittent hypoxia damages cerebellar cortex and deep nuclei. Neurosci Lett (2004) 1.29
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin (2006) 1.28
Cerebral metabolic impairment in patients with obstructive sleep apnoea: an independent association of obstructive sleep apnoea with white matter change. J Neurol Neurosurg Psychiatry (2001) 1.23
Multisite reliability of cognitive BOLD data. Neuroimage (2010) 1.20
Relationship between obstructive sleep apnea severity and brain activation during a sustained attention task. Sleep (2009) 1.19
Hippocampal neurogenesis is reduced by sleep fragmentation in the adult rat. Neuroscience (2007) 1.13
A novel method for quantifying scanner instability in fMRI. Magn Reson Med (2010) 1.13
Sleep deprivation can inhibit adult hippocampal neurogenesis independent of adrenal stress hormones. Am J Physiol Regul Integr Comp Physiol (2008) 1.10
Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med (2006) 1.09
Brain activation changes before and after PAP treatment in obstructive sleep apnea. Sleep (2009) 1.06
Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep (2005) 1.02
Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav Brain Res (2007) 1.01
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. Int Dig Health Legis (1997) 0.99
The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea. J Sleep Res (2009) 0.99
Persistent sleepiness in CPAP treated obstructive sleep apnea patients: evaluation and treatment. Sleep Med Rev (2007) 0.97
Sleepiness and residual sleepiness in adults with obstructive sleep apnea. Respir Physiol Neurobiol (2003) 0.96
fMRI reliability in subjects with stroke. Exp Brain Res (2007) 0.95
Altered brain activation during response inhibition in obstructive sleep apnea. J Sleep Res (2009) 0.95
Positron emission tomography findings in obstructive sleep apnea patients with residual sleepiness treated with continuous positive airway pressure. J Physiol Pharmacol (2007) 0.93
D-amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl) (2003) 0.92
Influence of sleep apnea on 24-hour blood pressure. Chest (1997) 0.90
Determinants of subjective sleepiness in suspected obstructive sleep apnoea. J Sleep Res (2008) 0.89
Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep (2006) 0.87
Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig (2009) 0.86
The potentially harmful medical consequences of untreated sleep-disordered breathing: the evidence supporting brain damage. J Am Dent Assoc (2009) 0.85
Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath (2008) 0.84
A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc (2010) 0.82